article Open AccessTop 10% cited
Clinical Significance of Programmed Death-1 Ligand-1 and Programmed Death-1 Ligand-2 Expression in Human Esophageal Cancer
Clinical Cancer Research · 2005 · Vol. 11(8) · pp. 2947–2953
Yuichiro Ohigashi✉Masayuki ShoYukishige YamadaYoshikazu TsuruiKaoru HamadaNaoya IkedaTakashi MizunoRyo YorikiHisanori KashizukaKatsunari Yane(Nara Medical University)Fumihiko Tsushima(Tokyo Medical and Dental University)Noriko Otsuki(Tokyo Medical and Dental University)Hideo Yagita∥(Juntendo University)Miyuki Azuma(Tokyo Medical and Dental University)Yoshiyuki Nakajima
Abstract
These data suggest that PD-L1 and PD-L2 status may be a new predictor of prognosis for patients with esophageal cancer and provide the rationale for developing novel immunotherapy of targeting PD-1/PD-L pathway.
Cancer-related Molecular PathwaysPancreatic and Hepatic Oncology ResearchLung Cancer Treatments and MutationsPD-L1Esophageal cancerImmunohistochemistryCancerImmunotherapyCancer researchCD8Clinical significanceMedicineMonoclonal antibody
MeSH terms
AgedEsophageal NeoplasmsEsophagusFemaleHumansImmunohistochemistryMaleMembrane GlycoproteinsMiddle AgedPeptidesPrognosisRNA, MessengerAntigens, CDGene Expression Regulation, NeoplasticSurvival Analysis
Citations
789
FWCI
7.55
field-weighted impact
References
33
Percentile
98%
vs. same field & year
Citations per year
Cited by
Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape
Science Translational Medicine · 2012 · 2,123 citations
PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations
Science Translational Medicine · 2016 · 2,413 citations
Prognostic and predictive value of PDL1 expression in breast cancer
Oncotarget · 2014 · 496 citations
Clinical Significance and Therapeutic Potential of the Programmed Death-1 Ligand/Programmed Death-1 Pathway in Human Pancreatic Cancer
Clinical Cancer Research · 2007 · 895 citations
PD‐1/PD‐L1 immune checkpoint: Potential target for cancer therapy
Journal of Cellular Physiology · 2018 · 506 citations
Recurrent glioma clinical trial, CheckMate-143: the game is not over yet
Oncotarget · 2017 · 415 citations
Overexpression of PD-L1 Significantly Associates with Tumor Aggressiveness and Postoperative Recurrence in Human Hepatocellular Carcinoma
Clinical Cancer Research · 2009 · 812 citations
PD-L1 regulates the development, maintenance, and function of induced regulatory T cells
The Journal of Experimental Medicine · 2009 · 2,023 citations
References
Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death.
The EMBO Journal · 1992 · 3,162 citations
B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion
Nature Medicine · 1999 · 2,463 citations
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
Nature Medicine · 2002 · 4,970 citations
Development of Lupus-like Autoimmune Diseases by Disruption of the PD-1 Gene Encoding an ITIM Motif-Carrying Immunoreceptor
Immunity · 1999 · 2,706 citations
PD-L2 is a second ligand for PD-1 and inhibits T cell activation
Nature Immunology · 2001 · 2,931 citations
Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation
The Journal of Experimental Medicine · 2000 · 5,184 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.